Tuesday, October 13, 2026

BTC $83,871 ▲ 2.61%

NewsLive Wire Politics World Markets Digital Assets Technology Sports

FranchisesThe Brief The Big Read The Breakdown Crypto Culture

MoreDeFi & On-Chain U.S. Equities Macro & Rates Research

LIVE

ADA$0.239+2.71%ETH$2,532+3.62%LINK$13.08+3.69%SOL$108.71+2.93%BTC$83,871+2.61%XRP$1.38+2.83%S&P 5007,807−0.06%Nasdaq27,246−0.44%Dow51,851+0.38%RUT2,794−0.45%TNX5.24%−0.08%TYX5.60%−0.04%FVX5.02%−0.04%IRX4.05%−0.17%VIX15.59+2.50%GOLD$4,215.50+0.59%SILVER$60.85+0.56%OIL$92.23−1.61%DXY102.26−0.32%NVDA$226.32−1.29%AAPL$340.97+1.29%TSLA$378.03−1.22%META$742.96+3.38%MSFT$541.15+1.14%AMZN$259.53−1.11%GOOGL$352.72+0.30%Fear & Greed57 — GreedADA$0.239+2.71%ETH$2,532+3.62%LINK$13.08+3.69%SOL$108.71+2.93%BTC$83,871+2.61%XRP$1.38+2.83%S&P 5007,807−0.06%Nasdaq27,246−0.44%Dow51,851+0.38%RUT2,794−0.45%TNX5.24%−0.08%TYX5.60%−0.04%FVX5.02%−0.04%IRX4.05%−0.17%VIX15.59+2.50%GOLD$4,215.50+0.59%SILVER$60.85+0.56%OIL$92.23−1.61%DXY102.26−0.32%NVDA$226.32−1.29%AAPL$340.97+1.29%TSLA$378.03−1.22%META$742.96+3.38%MSFT$541.15+1.14%AMZN$259.53−1.11%GOOGL$352.72+0.30%Fear & Greed57 — Greed

Tag

syndax pharmaceuticals

1 article

U.S. Equities2h ago

Syndax's IPF Setback Forces Growth Bet on Niktimvo and Revuforj

Axatilimab failed to slow lung decline in Phase 2, forcing Syndax to abandon IPF expansion and lean on existing oncology and GVHD franchises to hit 2029 targets.